Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a light device replace steroid sprays for hay fever?

NCT ID NCT05919316

Symptom relief Sponsor: National University of Malaysia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a home-use light device (rhinophototherapy) can reduce nasal inflammation and allergy symptoms as well as a standard steroid spray. Thirty-five adults with allergic rhinitis used either the light device for 4.5 minutes three times daily or a steroid spray once daily for two weeks. Researchers measured symptom scores, nasal airflow, and looked at tissue samples for inflammation and damage.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
rhinophototherapy (light device) and mometasone furoate nasal spray (steroid)
What this could lead to
If it works, this could offer a drug-free option for managing allergic rhinitis symptoms at home.
What could go wrong
This is a small, completed trial with only 35 participants, so results may not apply to everyone. The device requires daily use and may not be more effective than standard sprays.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

35 people

The number who actually took part.

Started

Jul 2023

Finished

Nov 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients 18 years and above * Newly diagnosed allergic rhinitis * Allergic rhinitis is confirmed via positive skin prick test or serum Immunoglobulin E Exclusion Criteria: * Anaphylaxis /poorly controlled bronchial asthma * Refused nasal biopsy * Usage of intranasal corticosteroids and/or antihistamine sprays for the past 1 month * Consumption of oral leukotriene receptor antagonist or oral steroids for the past 1 month * Concomitant nasal pathology (malignancy, chronic rhinosinusitis with nasal polyposis, severe deviated nasal septum) * Bleeding disorder or on anticoagulant/antiplatelet therapy * Recent URTI/Covid-19 within past 14 days * Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Allergic rhinitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

allergic rhinitis Rhinitis, Allergic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Allergic rhinitis

Contacts and locations

Locations

  • Otorhinolaryngology Department, Head and Neck Surgery, Faculty of Medicine, UKM Medical Centre, Jalan Yaacob Latif, Bandar Tun Razak, Cheras

    Kuala Lumpur, Cheras, 56000, Malaysia

More trials for these conditions

Other studies related to the condition(s) this trial covers.